The Effect of Clindamycin & a Live Biotherapeutic on the Reproductive

Status Recruiting

Clinical Trial Summary

Study question: Does antibiotic alone or in combination with live biotherapeutic treatment of an abnormal vaginal microbiota improve the reproductive outcomes of IVF couples? Study hypothesis: The investigator hypothesize that treatment of the reproductive tract pathogens and restoration of vaginal Lactobacillus will improve the reproductive outcomes of IVF patients. What is known already? Ultra-deep sequencing methods enable the refinement of reproductive tract microbiology in infertile patients. A recent meta-analysis reported that 19% of infertile patients had abnormal vaginal microbiota Moreover, someone have detected the presence of a Gardnerella (G.) vaginalis dominated endometrial biofilm in 50% of non-infertile patients with abnormal vaginal microbiota undergoing curettage; thus the treatment of such an endometrial biofilm might play an important role for the endometrial receptivity and subsequently the clinical pregnancy rate. Pilot study: In a recent pilot study it was observed that an abnormal vaginal microbiota negatively affects the clinical pregnancy rate in IVF patients. In this study the prevalence of abnormal vaginal microbiota was 28% (36/130) and only 9% of patients with qPCR defined abnormal vaginal microbiota obtained a clinical pregnancy (p=0.004). This association remained significant in an adjusted analysis. Furthermore, the invetigators have preliminary results demonstrating that vaginal bacteria such as G. vaginalis can be found in the endometrium of IVF patients, which is also supported by recent publications What is the novelty of this study? To the investigators knowledge, no previous treatment study of abnormal reproductive tract microbiota has been performed in IVF patients; this relatively small intervention holds the potential to increase the baby-take-home rate after IVF treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05166746
Study type	Interventional
Source	Regionshospitalet Viborg, Skive
Contact	Thor Haahr, MD
Phone	+4527885402
Email	thohaa@rm.dk
Status	Recruiting
Phase	Phase 2
Start date	December 7, 2017
Completion date	October 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05969574` - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting	`NCT05358483` - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting	`NCT05969795` - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support	Phase 1
Recruiting	`NCT06051201` - Innovation for Small-scale Experiments: ReceptIVFity Test	N/A
Completed	`NCT03177538` - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders	Phase 4
Completed	`NCT03638856` - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy	N/A
Completed	`NCT04052464` - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn	`NCT04753736` - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC	N/A
Completed	`NCT03349905` - Deferred Versus Fresh Embryo Transfers	N/A
Completed	`NCT05076981` - Progesterone Levels During Ovulation and Luteal Phase
Completed	`NCT04096027` - Cabergoline Before or After Oocyte Collection for Follicular Resolution	Phase 4
Recruiting	`NCT05980091` - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.	Phase 1
Terminated	`NCT01933633` - Improved Fertility After Exercise in Overweight/Obese Women	N/A
Terminated	`NCT01202643` - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF	Phase 1/Phase 2
Completed	`NCT01202656` - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)	Phase 1/Phase 2
Completed	`NCT01408615` - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation	`NCT05698550` - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET	Phase 3
Not yet recruiting	`NCT03910582` - Personalized FET in RIF Patients With Displaced Dating	N/A
Completed	`NCT05440019` - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed	`NCT05130125` - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effect of Clindamycin and a Live Biotherapeutic on the Reproductive Outcomes of IVF Patients With Abnormal Vaginal Microbiota

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms